Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement
that CPP-109 isintended for the treatment of a serious or life-threatening condition forwhich there is no effective treatment and which demonstrates the potentialto address unmet medical needs. For more information about the Company goto http://www.catalystpharma.com .
Date:6/3/2008